Detalles: Atopic Dermatitis (AD) is an inflammatory and chronic disease with a growing prevalence worldwide, high in the child population (20-25 percent) and lower, but also important, in the adult population (1-3 percent).

The disease in its moderate and severe forms emerges with a strong systemic inflammatory load, which on multiple occasions associates comorbidities at the level of other organs and systems different to the skin, and has a strong impact on the quality of life of patients, affecting to all spheres of an individuals life.

Nowadays, the etiopathogenesis is not known, but it is postulated that there is a genetic basis, a dysfunction at the level of the epidermal barrier, an alteration of the microbiota, with a greatly increased presence of Staphylococcus aureus, and finally, a dysregulation of the immune system, specifically, an over-activation of the type 2 immune response.

Fortunately, most patients present mild forms of the disease that are controlled with emollients and topical treatments, but around 10 percent of them present severe forms and require systemic treatments.

Until recently, treatment for moderate or severe forms comprised only phototherapy and classical immunosuppressive systemic therapy (oral corticosteroids and corticosteroid-sparing agents, such as oral Cyclosporine). Today there are approved new molecules such as the monoclonal antibody against the interleukin 4 and 13 receptor, Dupilumab, and the JAK 1 and 2 inhibitor, Baricitinib, among others. However, there are many other drugs in development that are presenting good efficacy and safety data in clinical trials. Therfore, a promising therapeutic future for patients with atopic dermatitis is coming.